Neutrophil-Lymphocyte Ratio in Different Stages of Breast Cancer
Despite many advances in the treatment of breast cancer, it is still the second most common cause of death in women in the United States. It has been shown that inflammation plays a major role in the treatment of these cancers and inflammatory factors enhance tumor growth, invasion, metastasis, and vascularization. In this study, we would like to analyze peripheral blood neutrophil-lymphocyte ratio (NLR) in breast cancer patients and its correlation with disease staging. This cross-sectional analytic study was conducted in Imam Hospital, affiliated with Tehran University of Medical Sciences; a total of 195 female patients with breast cancer met the inclusion criteria. All of the patients had a complete blood count with leukocyte differential performed before chemotherapy. Medical records including pathology reports were also available. Data for all patients were collected prior to any surgical intervention. Exclusion criteria included clinical evidence of active infection, presence of hematological disorders, acute as well as chronic inflammatory or autoimmune diseases, or prior steroid therapy. Higher platelet count was significantly associated with the higher stage. The stage was not associated with the hemoglobin level. There was no association between the tumor size and age of patients with NLR. There was a significant relationship between NLR and IDC. There was a significant relationship between IDC and NLRs of less than 8.1 and greater than 3.3. There was a significant relationship between NLR and vascular invasion. There was no association between NLR and estrogen receptor and HER2. There was no significant relationship between the PLR and the cancer stage. In this study, NLR showed a significant relation with the disease staging. As the NLR increases the stage increases as well. Therefore, this ratio may be helpful in the preoperative evaluation of patients with breast cancer.
Jemal, A., et al., Cancer statistics, 2006. CA: a cancer journal for clinicians, 2006. 56(2): p. 106-130.
Bonastre, J., et al., Metastatic breast cancer: we do need primary cost data. The Breast, 2012. 21(3): p. 384-388.
Brunicardi, F.C., Schwartz's principles of surgery. 2005: McGraw-Hill, Health Pub. Division.
Sotiriou, C., et al., Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences, 2003. 100(18): p. 10393-10398.
Schmidt, H., et al., Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. Journal of Clinical Oncology, 2007. 25(12): p. 1562-1569.
Teramukai, S., et al., Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. European journal of cancer, 2009. 45(11): p. 1950-1958.
Lin, M.S., et al., Elevation of platelet count in patients with colorectal cancer predicts tendency to metastases and poor prognosis. Hepato-gastroenterology, 2012. 59(118): p. 1687-1690.
Pierce, B.L., et al., Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. Journal of Clinical Oncology, 2009. 27(21): p. 3437-3444.
Mantovani, A., et al., Tumour immunity: effector response to tumour and role of the microenvironment. The lancet, 2008. 371(9614): p. 771-783.
Forget, P., et al., Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Annals of surgical oncology, 2013. 20(3): p. 650-660.
Hung, H.-Y., et al., Effect of preoperative neutrophil–lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. International journal of colorectal disease, 2011. 26(8): p. 1059-1065.
Keizman, D., et al., Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. The oncologist, 2012. 17(12): p. 1508-1514.
Sarraf, K.M., et al., Neutrophil/lymphocyte ratio and its association with survival after complete resection in non–small cell lung cancer. The Journal of thoracic and cardiovascular surgery, 2009. 137(2): p. 425-428.
Kishi, Y., et al., Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Annals of surgical oncology, 2009. 16(3): p. 614-622.
Yamanaka, T., et al., The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology, 2007. 73(3-4): p. 215-220.
Halazun, K.J., et al., Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Annals of surgery, 2009. 250(1): p. 141-151.
Aliustaoglu, M., et al., The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepato-gastroenterology, 2009. 57(99-100): p. 640-645.
Krenn-Pilko, S., et al., The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumor Biology, 2014: p. 1-8.
Proctor, M., et al., An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. British journal of cancer, 2011. 104(4): p. 726-734.
Van't Veer, L.J., et al., Gene expression profiling predicts clinical outcome of breast cancer. nature, 2002. 415(6871): p. 530-536.
Balkwill, F. and A. Mantovani, Inflammation and cancer: back to Virchow? The lancet, 2001. 357(9255): p. 539-545.
Mantovani, A., et al., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in immunology, 2002. 23(11): p. 549-555.
Noh, H., M. Eomm, and A. Han, Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. Journal of breast cancer, 2013. 16(1): p. 55-59.
Azab, B., et al., Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Medical oncology, 2013. 30(1): p. 1-11.
Chen, J., et al., Prognostic value of neutrophil‐to‐lymphocyte ratio in breast cancer. FEBS open bio, 2015. 5(1): p. 502-507.
Koh, Y.W., et al., Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumor Biology, 2014. 35(10): p. 9823-9830.